Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc at B. Riley Oncology Investor Conference (Virtual) Transcript

Jan 20, 2021 / 06:00PM GMT
Release Date Price: $48.91 (-3.97%)
Justin Howard Walsh
B. Riley Securities, Inc., Research Division - Research Analyst

Thank you for taking the time to join us at the B. Riley Oncology Investor Conference. My name is Justin Walsh, and I'm a biotech analyst, a new addition to the B. Riley team.

For this session, we're sitting down for a fireside chat with Iovance Biotherapeutics. As we talk, feel free to submit any questions on the platform. While we might not get to every question, we'll do our best to answer as many as the time allows.

Questions & Answers

Justin Howard Walsh
B. Riley Securities, Inc., Research Division - Research Analyst

So to jump right in and to start off, can you introduce yourself and provide a brief overview of the Iovance story?

Maria Fardis
Iovance Biotherapeutics, Inc. - CEO, President & Director

Absolutely. Hi. Good morning. Thank you for the invitation. My name is Maria Fardis. I'm President and CEO here at Iovance Biotherapeutics. We are a company developing cell therapy for solid tumors, and we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot